Literature DB >> 23785205

Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.

Soila Sukupolvi-Petty1, James D Brien, S Kyle Austin, Bimmi Shrestha, Sherri Swayne, Kristen Kahle, Benjamin J Doranz, Syd Johnson, Theodore C Pierson, Daved H Fremont, Michael S Diamond.   

Abstract

Although prior studies have characterized the neutralizing activities of monoclonal antibodies (MAbs) against dengue virus (DENV) serotypes 1, 2, and 3 (DENV-1, DENV-2, and DENV-3), few reports have assessed the activity of MAbs against DENV-4. Here, we evaluated the inhibitory activity of 81 new mouse anti-DENV-4 MAbs. We observed strain- and genotype-dependent differences in neutralization of DENV-4 by MAbs mapping to epitopes on domain II (DII) and DIII of the envelope (E) protein. Several anti-DENV-4 MAbs inefficiently inhibited at least one strain and/or genotype, suggesting that the exposure or sequence of neutralizing epitopes varies within isolates of this serotype. Remarkably, flavivirus cross-reactive MAbs, which bound to the highly conserved fusion loop in DII and inhibited infection of DENV-1, DENV-2, and DENV-3, more weakly neutralized five different DENV-4 strains encompassing the genetic diversity of the serotype after preincubation at 37°C. However, increasing the time of preincubation at 37°C or raising the temperature to 40°C enhanced the potency of DII fusion loop-specific MAbs and some DIII-specific MAbs against DENV-4 strains. Prophylaxis studies in two new DENV-4 mouse models showed that neutralization titers of MAbs after preincubation at 37°C correlated with activity in vivo. Our studies establish the complexity of MAb recognition against DENV-4 and suggest that differences in epitope exposure relative to other DENV serotypes affect antibody neutralization and protective activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23785205      PMCID: PMC3754038          DOI: 10.1128/JVI.01314-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  88 in total

1.  Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein.

Authors:  S Bhardwaj; M Holbrook; R E Shope; A D Barrett; S J Watowich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.

Authors:  Richard J Kuhn; Wei Zhang; Michael G Rossmann; Sergei V Pletnev; Jeroen Corver; Edith Lenches; Christopher T Jones; Suchetana Mukhopadhyay; Paul R Chipman; Ellen G Strauss; Timothy S Baker; James H Strauss
Journal:  Cell       Date:  2002-03-08       Impact factor: 41.582

3.  Structures of immature flavivirus particles.

Authors:  Ying Zhang; Jeroen Corver; Paul R Chipman; Wei Zhang; Sergei V Pletnev; Dagmar Sedlak; Timothy S Baker; James H Strauss; Richard J Kuhn; Michael G Rossmann
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

4.  Dengue vaccine development: a 75% solution?

Authors:  Scott B Halstead
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

5.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

6.  Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.

Authors:  Alena Atrasheuskaya; Peter Petzelbauer; Terry M Fredeking; George Ignatyev
Journal:  FEMS Immunol Med Microbiol       Date:  2003-01-21

7.  Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.

Authors:  Joshua M Costin; Elena Zaitseva; Kristen M Kahle; Cindo O Nicholson; Dawne K Rowe; Amanda S Graham; Lindsey E Bazzone; Greg Hogancamp; Marielys Figueroa Sierra; Rachel H Fong; Sung-Tae Yang; Li Lin; James E Robinson; Benjamin J Doranz; Leonid V Chernomordik; Scott F Michael; John S Schieffelin; Sharon Isern
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

8.  DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells.

Authors:  Boonrat Tassaneetrithep; Timothy H Burgess; Angela Granelli-Piperno; Christine Trumpfheller; Jennifer Finke; Wellington Sun; Michael A Eller; Kovit Pattanapanyasat; Suttipant Sarasombath; Deborah L Birx; Ralph M Steinman; Sarah Schlesinger; Mary A Marovich
Journal:  J Exp Med       Date:  2003-04-07       Impact factor: 14.307

9.  Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].

Authors:  Katherine L Williams; Soila Sukupolvi-Petty; Martina Beltramello; Syd Johnson; Federica Sallusto; Antonio Lanzavecchia; Michael S Diamond; Eva Harris
Journal:  PLoS Pathog       Date:  2013-02-14       Impact factor: 6.823

10.  Cryo-EM structure of the mature dengue virus at 3.5-Å resolution.

Authors:  Xiaokang Zhang; Peng Ge; Xuekui Yu; Jennifer M Brannan; Guoqiang Bi; Qinfen Zhang; Stan Schein; Z Hong Zhou
Journal:  Nat Struct Mol Biol       Date:  2012-12-16       Impact factor: 15.369

View more
  49 in total

Review 1.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.

Authors:  Aravinda M de Silva; Eva Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 2.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

Review 3.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

Review 4.  Temperature dependent conformational change of dengue virus.

Authors:  Xinzheng Zhang; Lei Sun; Michael G Rossmann
Journal:  Curr Opin Virol       Date:  2015-05-13       Impact factor: 7.090

Review 5.  A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes.

Authors:  Edgar Davidson; Benjamin J Doranz
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

6.  Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.

Authors:  Ellen Young; Robert H Carnahan; Daniela V Andrade; Nurgun Kose; Rachel S Nargi; Ethan J Fritch; Jennifer E Munt; Michael P Doyle; Laura White; Thomas J Baric; Mark Stoops; Aravinda DeSilva; Longping V Tse; David R Martinez; Deanna Zhu; Stefan Metz; Marcus P Wong; Diego A Espinosa; Magelda Montoya; Scott B Biering; Soila Sukulpolvi-Petty; Guillermina Kuan; Angel Balmaseda; Michael S Diamond; Eva Harris; James E Crowe; Ralph S Baric
Journal:  Cell Host Microbe       Date:  2020-05-13       Impact factor: 21.023

7.  Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies.

Authors:  Elinor Willis; Scott E Hensley
Journal:  Virology       Date:  2017-05-02       Impact factor: 3.616

Review 8.  Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host.

Authors:  Richard J Kuhn; Kimberly A Dowd; Carol Beth Post; Theodore C Pierson
Journal:  Virology       Date:  2015-03-30       Impact factor: 3.616

9.  A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.

Authors:  Atsushi Yamanaka; Tomohiro Kotaki; Eiji Konishi
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

Review 10.  HCV E2 core structures and mAbs: something is still missing.

Authors:  Matteo Castelli; Nicola Clementi; Giuseppe A Sautto; Jennifer Pfaff; Kristen M Kahle; Trevor Barnes; Benjamin J Doranz; Matteo Dal Peraro; Massimo Clementi; Roberto Burioni; Nicasio Mancini
Journal:  Drug Discov Today       Date:  2014-08-27       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.